Biggest News Aggregation in the World
📰 Alkermes News

Page 25 - Alkermes News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.

BioAesthetics Welcomes Joseph Nixon to its Board of Directors

DURHAM, N.C.--(BUSINESS WIRE)--BioAesthetics Corporation announced today the appointment of Mr. Joseph Nixon to its Board of Directors. Mr. Nixon brings over 25 years of life sciences investing and operating experience to BioAesthetics. He currently serves as Chief Financial Officer for Locus Biosciences, a biopharm...
North Carolina United States Nicholas Pashos Joseph Nixon Carolina Biotechnology Center Bioaesthetics Corporation

Pictet Asset Management SA Increases Holdings in Alkermes plc (NASDAQ:ALKS)

Pictet Asset Management SA grew its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 279.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,772,291 shares of the company’s stock after acquiring an additional 2,040,819 shares during the quarter. Pictet Asset Management SA owned […]
United States Christian Todd Nichols Piper Sandler Catot Laurencin Renaissance Technologies Jpmorgan Chase Co
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

179,000 Shares in Alkermes plc (NASDAQ:ALKS) Purchased by Integral Health Asset Management LLC

Integral Health Asset Management LLC purchased a new position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 179,000 shares of the company’s stock, valued at approximately $5,046,000. Other large investors have also modified their holdings of the company. Cibc World Markets Corp acquired […]
United States Christian Todd Nichols Catot Laurencin Piper Sandler Cantor Fitzgerald Putnam Investments

SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
United States Dana Farber Cancer Institute Bristol Myers Squibb Roche Genentech Calithera Biosciences Tonik Choueiri

Eagle Asset Management Inc. Purchases 161,434 Shares of Alkermes plc (NASDAQ:ALKS)

Eagle Asset Management Inc. increased its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 25.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 802,279 shares of the company’s stock after acquiring an additional 161,434 shares during the period. Eagle Asset Management […]
United States Catot Laurencin Piper Sandler Christian Todd Nichols Cantor Fitzgerald Jpmorgan Chase Co
Source: wkrb13.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science